LH LABCORP HOLDINGS INC.
Services-Medical Laboratories · NYSE · SEC CIK 920148 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.0%
TTM net income YoY17.4%
TTM EPS YoY19.7%
Revenue 3-yr CAGR6.6%
Net income 3-yr CAGR14.9%
Margins
Gross margin29.0%
Operating margin10.3%
Net margin6.9%
FCF margin8.8%
EBITDA margin15.1%
Returns
ROE11.4%
ROA5.4%
ROIC (approx.)8.6%
Asset turnover0.78x
Leverage & solvency
Liabilities / assets53.2%
Debt / equity0.66x
Current ratio1.41x
Interest coverage6.52x
Cash quality & payout
Operating cash flow / net income1.81x
Accruals ratio-4.4%
Payout ratio23.6%
Capex / revenue3.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $13.95B | $13.01B |
| Cost of revenue | $9.94B | $9.38B |
| Gross profit | $4.01B | $3.62B |
| SG&A expense | $2.22B | $2.23B |
| Operating income | $1.38B | $1.09B |
| Interest expense | $224.10M | $208.30M |
| Pretax income | $728.90M | $629.70M |
| Income tax | $229.80M | $212.40M |
| Net income | $876.50M | $746.00M |
| EBITDA | $2.07B | $1.73B |
| EPS (basic) | 10.54 | 8.89 |
| EPS (diluted) | 10.46 | 8.84 |
| Dividends declared per share | 2.88 | 2.88 |
| Weighted avg. shares (diluted) | 83.80M | 84.40M |
| Balance sheet | ||
| Cash & equivalents | $532.30M | $1.52B |
| Receivables | $2.10B | $1.94B |
| Inventory | $534.70M | $493.20M |
| Current assets | $4.02B | $4.81B |
| PP&E, net | $3.08B | $3.05B |
| Goodwill | $6.79B | $6.37B |
| Intangibles | $3.60B | $3.49B |
| Total assets | $18.39B | $18.38B |
| Current liabilities | $2.82B | $3.33B |
| Short-term debt | $500.10M | $1.00B |
| Long-term debt | $5.08B | $5.33B |
| Total debt | $5.58B | $6.33B |
| Total liabilities | $9.76B | $10.31B |
| Shareholders' equity | $8.62B | $8.05B |
| Net debt | $5.05B | $4.81B |
| Shares outstanding | 82.20M | 83.40M |
| Cash flow statement | ||
| Operating cash flow | $1.64B | $1.59B |
| Capital expenditure | $434.50M | $489.90M |
| Free cash flow | $1.21B | $1.10B |
| Investing cash flow | -$1.19B | -$1.37B |
| Financing cash flow | -$1.46B | $779.90M |
| Depreciation & amortization | $681.10M | $643.50M |
| Stock-based compensation | $125.80M | $116.70M |
| Dividends paid | $240.70M | $243.10M |
| Share buybacks | $450.00M | $250.10M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.